key: cord-0910166-gok0wn5b
authors: Aziz, Muhammad; Fatima, Rawish; Assaly, Ragheb
title: Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis
date: 2020-06-02
journal: J Med Virol
DOI: 10.1002/jmv.25948
sha: 66fdea08d7ba53c4a10f30574b58e1f850c13d60
doc_id: 910166
cord_uid: gok0wn5b

Interleukin-6 is an important marker of inflammation. We performed a systematic review and meta-analysis to demonstrate the association of elevated IL-6 with severe Coronavirus disease-2019 (COVID-19). A total of 9 studies were included in the systematic review and meta-analysis. Patients with severe COVID-19 had a significantly higher serum IL-6 levels compared to non-severe patients (mean difference (MD): 38.6 pg/mL, 95% CI: 24.3 - 52.9 pg/mL, p <0.001, I2 = 98.5%). On meta-regression, increasing mean IL-6 level was associated with increased mortality in patients (Coefficient (Q): 0.01, 95% CI: 0.01-0.03, p = 0.03). Given the association of elevated IL-6 with severe COVID-19 and mortality, clinicians should use this as a potential marker to recognize severe disease. IL-6 should be incorporated in a scoring system along with other inflammatory markers to risk stratify the patients for early recognition of severe disease. Our study should encourage researchers to conduct trial evaluating Anti IL-6 antibodies such as Tocilizumab to assess the efficacy in patients with severe COVID-19. This article is protected by copyright. All rights reserved.

To the Editor,

We read with interest the study by Luo shown in studies as an important predictor of severe COVID-19. 2,3 IL-6 is responsible for elevation of acute phase reactants, such as C-reactive protein, serum amyloid A, fibrinogen, and hepcidin, and inhibition of albumin synthesis. The dysregulated production of IL-6 has been attributed to autoimmunity and chronic inflammation. 4 We performed a systematic review and meta-analysis to compare IL-6 in severe and nonsevere patients.

An extensive literature search of PubMed/Medline, Embase, Cochrane, and Web of Sciences was conducted on 20 April 2020 to include all published studies. Two independent reviewers (MA and RF) screened and finalized articles, and performed data extraction. Any discrepancy during these steps was resolved through a mutual discussion. Severe COVID-19 was defined as either respiratory distress (rate ≥ 30/min, oxygen saturation ≤ 93% at rest, and/or PaO2/FiO2 ≤ 300 mm Hg), 5 ICU admission, and/or death. Continuous variables (using mean serum levels and standard deviation) were compared and mean difference (MD) was estimated with 95% confidence interval (CI), and P value less than .05 was considered as statistically significant. DerSimonian Laird method/random effects meta-analysis using Open Meta Analyst (CEBM, University of Oxford, Oxford, UK) was performed. Meta-regression was attempted if studies did not give a direct comparison between groups of interest. Coefficient (Q), 95% CI, P value (<.05 was considered statistically significant), and scatter plot were generated for regression analysis.

A total of nine studies with laboratory-confirmed 1426 patients (mean age: 53.0 ± 6.4 years, females: 46.6%) were included. All studies originated from China, and study duration ranged from 1 January to 28 February 2020. A comparison of mean serum IL-6 for severe COVID-19 and nonsevere COVID-19 was performed in seven studies. Based on our analysis, we suggest a cut-off of more than 55 pg/mL for identifying patients at high risk of severe COVID-19. Only one study directly compared mean serum IL-6 level for survivors and nonsurvivors. 5 Based on this, a cut-off of more than 80 pg/mL can be used for identifying patients at high risk of mortality.

The elevation of IL-6 has been previously demonstrated in inflammatory state for multiple conditions. 3 The pathophysiological hallmark of COVID-19 is the severe inflammation and chemokine storm, which explains the elevation of IL-6. 7, 8 The importance of identifying this elevated biomarker also lies in the potential use of antibody against IL-6 such as tociluzumab, which is currently undergoing a clinical trial. 9 Tociluzumab has previously shown efficacy against autoimmune and inflammatory conditions such as rheumatoid arthritis, systemic juvenile idiopathic arthritis,Castleman's disease, neuromyelitis optica, giant cell arteritis, and cytokine release syndrome. 10, 11 Based on our results, IL-6 is an important marker of inflammation and can guide the clinicians in recognizing patients with severe COVID-19 early in the disease course. Furthermore, researchers should develop a scoring system including IL-6 to assist clinicians in early recognition of patients at risk for developing severe disease. 

Tocilizumab treatment in COVID-19: a single center experience

Clinical and immunologic features in severe and moderate coronavirus disease 2019

COVID-19 in a designated infectious diseases hospital outside Hubei Province

IL-6 in inflammation, immunity, and disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical laboratory tests: which, why, and what do the results mean

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Tocilizumab in COVID-19 pneumonia

Tocilizumab: a review of its use in the management of rheumatoid arthritis

FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or lifethreatening cytokine release syndrome